Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Semiglazov Vf et al.|Annals of Oncology|2021Cited by 724
Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9Min Jiang, Kunwei Shen|Molecules|2013Cited by 109
Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen through Activation of Akt/mTOR SignalingXi Zhang, Kunwei Shen|PLoS ONE|2013Cited by 50
A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cellsOu Huang, Kunwei Shen|Oncology Reports|2014Cited by 6
Hippo/YAP Signaling Choreographs The Tumor Immune Microenvironment to Promote Triple Negative Breast Cancer Progression Via TAZ/IL-34 AxisZheng Wang, Kunwei Shen|Research Square|2021Cited by 6